SCHEMBL21389995

SCHEMBL21389995

CC(C)(C)OC(=O)N1CC(NC(=O)COc2ccc(Cl)c(F)c2)C1

nearest known ligand 0.59

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ATF4 P18848 18/20 0.59
HDAC8 Q9BY41 1/20 0.46
GPR119 Q8TDV5 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23294677 0.92 ATF4 (0.56) ATF4HDAC8
SCHEMBL21390155 0.92 ATF4 (0.56) ATF4HDAC8
SCHEMBL21384497 0.92 ATF4 (0.56) ATF4HDAC8
SCHEMBL21384496 0.92 ATF4 (0.56) ATF4HDAC8
SCHEMBL21390157 0.92 ATF4 (0.56) ATF4HDAC8
SCHEMBL29901237 0.91 ATF4 (0.53) ATF4HDAC8GPR119
SCHEMBL23706884 0.91 ATF4 (0.53) ATF4HDAC8GPR119
SCHEMBL22602020 0.91 ATF4 (0.59) ATF4GPR119
SCHEMBL22602172 0.91 ATF4 (0.59) ATF4GPR119
SCHEMBL29689471 0.91 ATF4 (0.59) ATF4GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240140919-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. 2024-05-02 US disclosed
US-20230250072-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. 2023-08-10 US disclosed
US-20230250072-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. 2023-08-10 US disclosed
US-20230250072-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. 2023-08-10 US disclosed
US-20210130308-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. 2021-05-06 US disclosed
US-20210130308-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. 2021-05-06 US disclosed
WO-2019183589-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. (US) 2019-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250072-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 EIF2A, EIF4A2, EIF4EBP1 ATF4 118/4885HDAC8 2068/4885GPR119 3690/4885
US-20210130308-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 EIF2A, EIF4A2, EIF4EBP1 ATF4 118/4885HDAC8 2068/4885GPR119 3690/4885
US-20240140919-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 EIF2A, EIF4A2, EIF4EBP1 ATF4 118/4885HDAC8 2068/4885GPR119 3690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.